Aisha Vadhariya

Eli Lilly and Company

Poster(s):

• P3177 - Mirikizumab Improves Quality of Life in Patients With Crohn’s Disease Up to 2 Years of Treatment: Results From the VIVID-2 Study
  Monday, October 27, 2025

  10:30 AM - 4:00 PM PDT

• P3178 - Patient-Level Dynamics of Clinical Response to Mirikizumab and Its Impact on Quality of Life: Analysis from the Vivid-1 Trial in Crohn’s Disease
  Monday, October 27, 2025

  10:30 AM - 4:00 PM PDT